High Expression of TTYH3 Predicts Poor Outcome in Hepatocellular Carcinoma

Abstract

Objective Analyze the expression level of TTYH3 gene in liver cancer, promoter methylation, gene mutation, co-expression, Immune infiltration, protein interaction and overall survival by database mining. Methods We utilized the UALCAN, GEPIA, cBioPortal, Metascape, STRING, TIMER, TISIDB, and MEXPRESS databases to investigate the transcription level, genetic alteration, methylation, and biological function of TTYH3 in HCC patients, and its association with the occurrence, progress, prognosis, and immune cell infiltration in patients with HCC. Results Multiple databases have confirmed that the mRNA level of TTYH3 in liver cancer tissues is significantly higher than that in normal tissues. UALCAN and GEPIA confirmed that the overexpression of TTYH3 mRNA was associated with clinical stage, and the expression of TTYH3 mRNA increased with the increase of stage (P<0.05). Multiple databases confirmed that the overexpression of TTYH3 gene was associated with low survival rate (P<0.05). cBioPortal database analysis showed that TTYH3 gene mutation was associated with low survival rate and poor prognosis (P<0.05). GEPIA search for genes co-expressed with TTYH3. Timer database showed that TTYH3 was involved in inflammatory response and immune cell infiltration. Methylation data from MEXPRESS indicate significant probe level variation of CpG island methylation status of the gene TTYH3, which was associated with low survival rate (P<0.05), Moreover, we also found that the expression of TTYH3 was significantly correlated with tumor-infiltrating lymphocytes and immunomodulators, The STRING protein analysis network showed that TTYH3 may interact with BEST1, BEST2, BEST3, BEST4, ZnF467, CLCC1, GLRB, ANO1, IQCE, ANO2 and other proteins. Conclusion Through a variety of databases, it was found that TTYH3 was highly expressed in liver cancer, and the expression level was related to the survival and prognosis of liver cancer patients. Found TTYH3 involved in inflammation and immune cell infiltration and influence the outcomes in patients with liver cancer clinical, TTYH3 promoter methylation of meaningful expression differences in liver cancer, the co-expressed genes, proteins interaction can be in-depth study, as well as TTYH3 gene and the relationship between the liver cancer, for the prognosis of liver cancer biomarkers and therapeutic targets.